Abstract
Talin-1 is a cytoskeleton protein that participates in cell migration and plays a role in tumor formation, migration, and metastasis in different types of cancer. Chinese investigators have observed that the levels of Talin-1 protein and mRNA expression in HCC tissues are significantly lower than in the adjacent non-cancerous tissue. However, Japanese investigators have reported that Talin-1 is upregulated in HCC. Tln2 as homologous gene of Tln-1, which encodes a very similar protein, but the role of Talin-2 is very little known in primary liver cancer (PLC). We investigated whether the expression of Talin-1 in PLC may be associated with the histological subtype as well as the role of Talin-1 in tumor cell invasion and migration using human hepatocellular carcinoma cell lines. We measured the mRNA expression levels of Talin-1 and Talin-2 in five human liver cancer cell lines and normal human liver cell (LO2 cell line) by real-time PCR and the protein expression levels of Talin-1 by Western blot. Migration and invasion of the cells were assessed using transwell assays and cell scratch experiments, respectively, and proliferation was assessed by soft AGAR colony formation. Talin-1 and Talin-2 expression differed significantly between the five human liver cancer cell lines and LO2 cell line (p<0.05). Compared with the LO2 cell line, the invasion and migration capabilities of the five cancer cell lines differed significantly (p<0.05). Similarly, the colony-forming ability differed (p<0.05). High levels of Talin-1 expression are correlated with reduced invasion and migration as well as decreased malignancy in human liver cancer cell lines; the suppression of Talin-1 promotes invasion and migration. In addition, Talin-2 may be correlated with invasion and migration in human hepatocellular carcinoma.
Highlights
Primary liver cancer is the fifth most common cancer worldwide (Schafer et al, 1999; Beer et al, 2002;Kirk et al, 2006; Farazi et al, 2006; Laurent et al, 2006; Zender et al, 2006; Hui, 2009)
We investigated whether the expression of Talin-1 in primary liver cancer (PLC) may be associated with the histological subtype as well as the role of Talin-1 in tumor cell invasion and migration using human hepatocellular carcinoma cell lines
We investigated whether the expression of Talin-1 in Hepatocellular carcinoma (HCC) may be associated with the histological subtype of HCC, we sought to determine the levels of Talin-1 expression in human liver cancer cell lines, to observe the relationship between Talin-1 expression and the invasion and migration of liver cancer cell lines, and to determine the relationship between Talin-1 expression and liver cancer cell colonization
Summary
Primary liver cancer is the fifth most common cancer worldwide (Schafer et al, 1999; Beer et al, 2002;Kirk et al, 2006; Farazi et al, 2006; Laurent et al, 2006; Zender et al, 2006; Hui, 2009). HCC, like other cancers, is characterized by a multistage process of tumor progression (Takayama et al, 1990; Kirk et al, 2006; Kanamori et al, 2011), including invasion of the surrounding tissues, migration, and the colonization of distant sites in the body. Talin-1 plays an essential role in integrin activation (Giancotti, 1999; Sakamoto et al, 2010). Chinese investigators observed that the levels of Talin-1 protein and mRNA expression in HCC tissues were significantly lower than in the adjacent non-cancerous tissue. Egyptian investigators have reported that Serum levels of TLN1 in hepatocellular carcinoma patients were significantly higher. We investigated whether the expression of Talin-1 in HCC may be associated with the histological subtype of HCC, we sought to determine the levels of Talin-1 expression in human liver cancer cell lines, to observe the relationship between Talin-1 expression and the invasion and migration of liver cancer cell lines, and to determine the relationship between Talin-1 expression and liver cancer cell colonization
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
